**G Protein–Coupled Receptors as Potential Drug Targets for Lymphangiogenesis and Lymphatic Vascular Diseases**

William P. Dunworth, Kathleen M. Caron

**Abstract**—G protein–coupled receptors (GPCRs) are widely expressed cell surface receptors that have been successfully exploited for the treatment of a variety of human diseases. Recent studies in genetically engineered mouse models have led to the identification of several GPCRs important for lymphatic vascular development and function. The adrenomedullin receptor, which consists of an oligomer between calcitonin receptor-like receptor and receptor activity modifying protein 2, is required for normal lymphatic vascular development and regulates lymphatic capillary permeability in mice. Numerous studies also suggest that lysophospholipid receptors are involved in the development of lymphatic vessels and lymphatic endothelial cell permeability. Given our current lack of pharmacological targets for the treatment of lymphatic vascular diseases like lymphedema, the continued identification and study of GPCRs in lymphatic endothelial cells may eventually lead to major breakthroughs and new pharmacological strategies for the treatment of lymphedema. *(Arterioscler Thromb Vasc Biol. 2009;29:650-656.)*

**Key Words:** angiogenesis, other treatment, animal models of human disease, endothelium, other vascular biology

G protein–coupled receptors (GPCRs) are widely expressed proteins that span the cell membrane 7 times and respond to a variety of stimuli including peptides, proteins, small organic compounds, lipids, amino acids, and cations. Recent estimates predict that humans have approximately 800 GPCRs which can be grouped into 5 major phylogenetic families: Rhodopsin, Secretin, Adhesion, Glutamate, and Frizzled/Taste2 families.\(^1\) A comprehensive review article exploring the diversity between GPCR families and its significance for drug design was recently published by Lagerström and Schiöth.\(^2\) In summary, GPCRs from every family are highly attractive targets for pharmacological manipulation by either recombinant proteins, small molecule compounds, allosteric ligands, or antibodies. There are currently 46 GPCRs that serve as drug targets for the treatment of a multitude of conditions including hypertension, pain, ulcers, allergies, alcoholism, obesity, glaucoma, psychotic disorders, and HIV. However, this leaves several hundreds of GPCRs as potential drug targets, and among those approximately 150 are still considered orphan receptors (receptors for which the endogenous ligand has yet to be identified).\(^2\) One major impediment to increasing the repertoire of pharmacologically useful GPCRs is our general lack of knowledge regarding the association of a putative GPCR with a precise physiological function or disease condition. Therefore, as scientists embark on the journey of elucidating the pathophysiology of complex and poorly treatable diseases, one beneficial approach may be to identify GPCRs associated with the condition, because they may eventually translate into effective drug targets.

**Diseases of the Lymphatic Vascular System and Current Therapies**

Diseases of the lymphatic vascular system serve as an example of how lack of knowledge about normal and diseased tissues has limited our ability to generate many effective pharmacological therapies. The lymphatic vascular system normally works to maintain tissue fluid homeostasis, absorb fatty acids and lipid-soluble vitamins from the gut, and traffic antigen-presenting immune cells through the lymph nodes. Therefore, failure of the lymphatic vascular system has devastating consequences.\(^3\) Lymphedema is the result of inadequate lymphatic function and if not properly managed can lead to debilitating and painful limb swelling, tissue fibrosis, inflammation, and increased susceptibility to infection. Lymphedema can be caused by rare genetically-inherited mutations resulting in abnormal development or function of the lymphatic vascular system either at birth, puberty, or adulthood.\(^3\) More common causes of lymphedema are attributable to physical disruption or damage to the lymphatic vasculature, either by surgery, radiation therapy, or infection with the mosquito parasites *Wuchereria bancrofti* or...
in industrialized countries, the occurrence of lymphedema is rapidly increasing, proportional to the increasing use of surgical and radiation therapies for life-saving cancer treatments. In many tropical and subtropical countries, parasitic filarial lymphedema or elephantiasis is endemic and affects approximately 120 million individuals worldwide. Regardless of the cause, lymphedema carries with it immense psychological and social sequelae and disability. Rockson has recently provided a survey of current treatment strategies for the management of lymphatic vascular disease. Currently, the most effective treatment for lymphedema consists of a multifaceted physiotherapeutic approach for improving lymphatic function through application of lymphatic-specific massage techniques, remedial exercise, fitted compression garments, and skin care. Although this all-inclusive approach is largely successful among compliant patients, the daily treatments and changes in lifestyle can cause undesirable financial, physical, and psychological strain for many patients.

Recent surgical approaches have provided limited relief to patients with severe lymphedema. For example, liposuction followed by sustained intense compression can relieve tissue congestion caused by collagen and fat deposition. However, liposuction only provides temporary relief from swelling and does not directly improve lymphatic function. Reconstructive microsurgery through lymphovenous anastomoses (in effect, lymphatic bypass surgery) can provide minimal relief but is largely ineffective.

Pharmacological therapies for lymphedema are extremely limited and largely controversial. Coumarin has been shown to reduce lymphedema, but its overall effectiveness and functional mechanism remain controversial. Moreover, long-term systemic treatment with coumarin is correlated with a high rate of hepatotoxicity. Antioxidants, including selenium and flavonoids, have also been explored as potential therapies, but preliminary investigations into their effectiveness have remained inconclusive.

The treatment for parasitic filarial lymphedema has had better success. Massive drug delivery programs, consisting of dual treatment with diethylcarbamazine and albendazole (antiparasitic agents), can effectively target and eliminate infecting parasites and reduce the burden of filarial lymphedema in large populations. However, treatment strategies for filariasis do not repair the previously damaged lymphatic vasculature within an individual.

Perhaps the most exciting progress toward pharmacological treatments for lymphedema has come from vascular endothelial growth factor C (VEGFC–based) therapies. As described below, VEGFC is a potent growth and migratory factor for lymphatic endothelial cells. In animal models of lymphedema, VEGFC-based therapies have been demonstrated to promote lymphangiogenesis. Even more promising has been the recent discovery that adenosinoreceptor-delivered VEGFC can induce the formation of functional collecting lymphatics as well as improve the outcomes of lymph node transplantations in mice. Other growth factors, including VEGFD, VEGFA, fibroblast growth factor-2, and hepatocyte growth factor, have also shown exciting promise as therapeutic lymphangiogenic agents in animal models.

Nevertheless, it remains clear that the identification of additional drug targets for the modulation of lymphatic growth or permeability is highly desirable. Because GPCRs are pharmacologically-tractable cell-surface receptors and are widely used for the treatment of human diseases, the identification of potentially useful GPCR targets for the modulation of lymphatic vascular growth or function would represent a major advancement in the field. In the following sections, we highlight recent discoveries from animal models that have uncovered novel roles for several GPCRs in lymphatic vascular development and function.

Lessons in Lymphangiogenesis From Gene Knockout Models

In the past 10 years, phenotypic characterization of gene knockout mouse models has resulted in remarkable progress toward identifying genes important in the development and function of the lymphatic vascular system. The impact that gene targeting has had on driving the field forward is unparalleled, and so it is fitting that the 2007 Nobel Prize in Physiology or Medicine was awarded to Smithies, Capecchi, and Evans in recognition of their efforts toward developing gene targeting approaches. Several elegant and fully comprehensive reviews have recently been published with in-depth details and insights on how the phenotypes of gene targeted animal models have built the foundation for understanding lymphangiogenesis.

Figure 1 summarizes our current understanding of the stepwise process of lymphangiogenesis and lists numerous genetic factors that have been identified as important for lymphangiogenesis through gene targeting approaches. Development of the lymphatic vascular system is initiated when lymphatic-endothelial-hyaluronan-receptor-1 (LYVE1) expressing endothelial cells of the cardinal vein begin to express the transcription factor sex determining region Y-box 18 (Sox18), which drives expression of prospero-related homebox 1 (Prox1) in a polarized manner. Sox18 and Prox1 transcriptionally reprogram venous endothelial cells so that they become specified toward a lymphatic fate. The upregulation of the VEGFC receptor, VEGFR3, in lymphatic endothelial cells confers their ability to sprout from the cardinal vein and migrate toward an ectopic gradient of growth-promoting VEGFC. The lymphatic endothelial cells organize into primary lymph sacs which eventually separate from the cardinal vein in a process dependent on several genes, including tyrosine kinase Syk and adaptor protein Slp76, phospholipase C gamma 2 (Plcy2) and sprouty-related, EVH1 domain 1 and 2 (Sprd1&2). Subsequent rounds of proliferation lead to the formation of a primary lymphatic plexus which is later remodeled with mural cells and luminal valves to form the fully functional lymphatic vascular network.

Progress toward elucidating these developmental steps has been steadfast over the past 10 years, with a handful of new genetic players identified every year. But only recently have GPCRs become implicated in lymphangiogenesis, and the
following sections highlight these new discoveries with an emphasis on how these receptors may be pharmacologically beneficial (summarized in Figure 2).

Calcitonin Receptor-Like Receptor

The calcitonin receptor-like receptor (CALCRL) belongs to the Secretin family of GPCRs; a small family of 15 receptors that bind peptide hormones and have extended extracellular N’-terminal hormone-binding domains. A distinguishing feature of several Secretin family receptors is their ability to associate with single-pass transmembrane proteins that can alter receptor trafficking, ligand binding, and downstream signaling. The identification and characterization of these 3 mammalian receptor activity modifying proteins (RAMP1–3) was first established with CALCRL, such that RAMP1 association with CALCRL produces a receptor with high affinity for calcitonin gene-related peptide (CGRP), whereas association with RAMP2 or RAMP3 produces a receptor with preferential binding to adrenomedullin (AM). Recently, a third endogenous peptide ligand, intermedin, was also shown to signal through CALCRL–RAMP complexes. Therefore, whether a cell responds to either CGRP, AM, or intermedin is largely dependent on the extent of RAMP expression. The unique ability of RAMPs to modulate receptor ligand binding properties has already been exploited in drug design. Two small molecule compounds that antagonize CGRP binding to the CALCRL–RAMP1 oligomer are currently in clinical trials for the management of pain associated with migraine. Although no compounds have yet been described for CALCLR–RAMP2 oligomers, our recent studies in genetically engineered mouse models suggest that CALCRL–RAMP2 oligomers may represent ideal drug targets for the lymphatic vasculature.

Several years ago, our laboratory began to systematically generate and comparatively phenotype gene knockout mice for all mammalian RAMPs, CALCRL, and AM with the hopes of identifying conserved (or divergent) phenotypes in which the use of RAMP-based compounds could be beneficial for the treatment of human diseases. The most striking of phenotypes, embryonic lethality at midgestation, occurs in knockout mice for AM, CALCRL, and RAMP2. Remarkably, each of these knockout mice shares a highly conserved appearance of generalized edema without hemorrhage, which not only provides compelling evidence that AM–CALCRL–RAMP2 constitutes a physiologically relevant signaling pathway but also suggests that the development of the lymphatic vascular system is abnormal. Indeed, the AM, CALCRL, and RAMP2 knockout mice all suffer...
from substantially smaller jugular lymphatic vessels attributable to significantly reduced proliferation of lymphatic endothelial cells compared to venous endothelial cells during midgestation.42 Elegant studies by Jin and colleagues also show that AM treatment of adult mice with tail lymphedema significantly improves lymphedema and promotes in vivo lymphangiogenesis.43

Although several studies demonstrate that AM can affect the proliferation, permeability, and growth of the blood vasculature,44,45 the prevalence of the lymphatic vascular defects in the knockout models is supported by numerous other studies. For example, comparative gene profiling studies between blood endothelial cells (BECs) and lymphatic endothelial cells (LECs) consistently demonstrate that CALCLR and RAMP2 are preferentially upregulated in the lymphatic lineage.46,47 Although some of this upregulation can be attributed to transcriptional regulation by the lymphatic-specific transcription factor Prox1,48 recent studies also suggest that downregulation of RAMP2 levels by a blood-enriched microRNA may equally contribute to the enhanced expression of RAMP2 in LECs (personal communication, Dr Michael Detmar, Zurich, Switzerland, 2009). Comparative gene profiling experiments also reveal that Complement Factor H, the serum binding protein for AM that enhances AM peptide activity by 2-fold,49 is significantly enriched in LEC compared to BECs.50 Finally, mice with genetic deletion of the enzyme required for functionally activating AM peptide through amidation, peptidylglycine α-amidating monooxygenase (PAM), precisely phenocopy the AM; CALCLR and RAMP2 knockout mice;51 though in depth characterization of the lymphatic vasculature has not yet been performed. Taken together, these studies demonstrate that several mechanisms are in place to ensure that the local bioactivity of AM peptide and the sensitivity to CALCLR–RAMP2 signaling are highly enriched in the lymphatic vasculature. This is further supported by our recent study demonstrating that the principal effect of subcutaneous AM peptide injection is to significantly decrease local lymphatic permeability in the dermal lymphatic vessels of the mouse tail.52 So, although the broad tissue distribution of CALCLR–RAMP2 may cause some hesitation for drug design (because of undesirable off-target side effects), the inherent sensitivity and upregulation of AM receptors in the lymphatic endothelium may prove to be highly beneficial.

**Lysophospholipid Receptors**

Lysophospholipid (LP) receptors belong to the *Rhodopsin* family of GPCRs and bind bioactive lipids to elicit a wide range of cellular effects. Originally known as endothelial differentiation gene receptors (Edg), these receptors are currently designated as either lysophosphatidic acid receptors (LPA1–3) or sphingosine-1-phosphate receptors (S1P1–5), reflective of their respective lipid ligands.53 LP receptors are nearly ubiquitously expressed and cells may express multiple subtypes.54 The bioactive lipid ligands LPA and S1P are also widely expressed but most highly produced by platelets, which when activated release LPA and S1P into the bloodstream in the micromolar range.54,55 LP receptor signaling has been shown to mediate angiogenesis, permeability, vascular tone, and cardiac function56–59 as well as participate in the immune response through regulation of lymphocyte trafficking.60–63 Currently, several preclinical and clinical stage studies are being undertaken, using both antagonist and agonist of LP receptors, in the hopes of providing therapies against tumor growth and metastasis.64–66 and autoimmune disorders including multiple sclerosis, kidney graft rejection, and inflammation.67–71

Recent genetic studies in zebrafish have demonstrated an essential role for LPA signaling in lymphatic vascular development since morpholino-based knockdown of zebrafish LPA (zlpal) resulted in failure of thoracic duct development.72 Interestingly, this phenotype was partially rescued by VEGFC overexpression, suggesting that LPA and VEGFC signaling may converge to promote lymphatic vessel development.72 In another study, ligand binding to LPA1/3 receptors on human umbilical venous endothelial cells (HUVECs) increased VEGFC expression and secretion.73,74 Remarkably, LPA stimulation also promoted the formation of Prox1 and podoplanin positive capillary tubes, suggesting that LPA signaling has the ability to confer lymphatic identity.74 Many studies demonstrate that LPA can modulate the paracellular permeability of the endothelial cell barrier.50 Although there are no reports specifically describing LPA-mediated effects on LEC permeability, the broad effects of LPA on endothelial cell function make it likely that LPA also affects LEC permeability. Gene targeted knockout mouse models of LPA1, LPA2, and LPA3 receptors do not display any cardiovascular developmental defects.75–77 However, mice null for autotaxin (ATX), the enzyme necessary for producing bioactive LPA, are embryonic lethal with severe vascular defects, suggesting that the LPA1–3 receptors may be functionally redundant in the developing vasculature.78 Given the recent evidence that LPA functions as a potent lymphangiogenic factor, extensive reevaluation of the LPA1–3 null mice for lymphatic vascular defects may be informative.

Sphingosine-1-phosphate activation of S1P1/3 receptors in LECs also promotes lymphangiogenesis both in vitro and in vivo.79 Compared to HUVECs, LECs expressed more S1P1/3 receptors and after stimulation with S1P, secreted more angiopoietin-2, a potent lymphangiogenic factor.80 Several studies have demonstrated that S1P signaling decreases endothelial cell permeability through reorganization of junctional proteins at the plasma membrane.81,82 Recent studies exploring lymphocyte trafficking into the lymphatic sinuses showed that S1P1 stimulation effectively tightened the lymphatic endothelial cell barrier, and these effects may be attributable to enhanced organization of junctional components including ZO-1, CD31, and β-catenin.83,84 The predominant phenotype of the S1P1 knockout mice is massive hemorrhage at midgestation caused by an endothelial-specific failure in vascular smooth muscle cell recruitment and vessel maturation.85,86 Mice lacking all 3 S1P receptors (S1P1, S1P2, and S1P3) had exacerbated vascular deficiencies compared to S1P1 knockout mice, whereas S1P2–S1P3 double knockout mice exhibited partial lethality with fragile endothelial cells prone to hemorrhage.85 These data suggest that S1P receptors have both redundant and cooperative functions during vascular development, but do not preclude the possibility that S1P signaling may play an important role in lymphatic vascular development or function.
Taken together, an increasing number of new studies, both in vivo and in vitro, suggest that lysophospholipid receptors may mediate important biological functions in the lymphatic vasculature, including lymphangiogenesis, vessel integrity, LEC permeability, and potential cross-talk with other lymphangiogenic factors. Because LP receptors are already being pharmacologically exploited for the treatment of human disease, future studies focused on the effects of lysophospholipids on the lymphatic vasculature may lead to new GPCR targets for the modulation of lymphatic growth or function.

Searching for Other GPCRs in Lymphatic Endothelial Cells

Because GPCR proteins are typically expressed at low levels in endogenous tissues, the use of proteomic profiling approaches for identifying lymphatic-specific GPCRs may prove problematic. Also, because antibodies directed against the extracellular domain of GPCRs can be difficult to generate or lack specificity, the use of immunohistochemical approaches to identify lymphatic-specific GPCRs may also provide limited benefit. So, perhaps the best approach lies in genome-wide transcriptional profiling approaches, where cohorts of genes that are differentially expressed between LECs and BECs can be identified and compared. Fortunately, several research groups have already performed these very informative and elegant experiments. In all of these studies, there exist at least 6 GPCRs that appear to be enriched in LECs, and most of them are still considered orphan receptors with no identified ligand. The importance of GPCR signaling in LECs is also supported by the increased expression in LECs of several GPCR signaling modifiers, like regulator of G-protein signaling 2 (RGS-2), RGS-16 and β-arrestin.47,49

Olfactory receptors are the largest class of GPCRs, with 388 predicted human receptors, and belong to the Rhodopsin receptor family. Nearly all are considered orphan receptors, and beyond the fragrance industry they have not generally been considered as candidate drug targets for human diseases. However, it is interesting to recognize that like the CALCRL–RAMP paradigm, several olfactory receptors have been associated with RAMP-like accessory proteins, called receptor accessory proteins (REEPs). Like RAMPs, REEPs can promote the surface expression of olfactory receptors and modulate their function. Interestingly, the Petrova et al study showed that REEP1 was overexpressed 2.5-fold more in LECs than in BECs. The broad tissue distribution of olfactory receptors beyond the olfactory epithelium suggests they may have other functions beyond smell. In fact, olfactory receptors have recently been implicated in kidney function and sperm chemotaxis. Although openly speculative, it is intriguing to consider that olfactory receptors enriched in lymphatic endothelium might serve as chemosensory factors for mediating developmental lymphangiogenesis or for sensing changes in interstitial fluid composition. Of course, future experiments using genetic engineering approaches in mice need to be undertaken to fully explore this hypothesis.

In conclusion, recent studies in genetically engineered mouse models have led to the identification of several GPCRs important for lymphatic vascular development and function. Given our current lack of pharmacological targets for the treatment of lymphatic vascular diseases like lymphedema, the continued identification and study of GPCRs in lymphatic endothelial cells may eventually lead to major breakthroughs and new pharmacological strategies for the treatment of lymphedema.

Acknowledgments

The authors thank Dr Michael Detmar, Zurich, Switzerland for helpful discussions and Kimberly Fritz-Six for her assistance in generation of Figures.

Sources of Funding

This work was supported in part by an AHA Predoctoral Fellowship (0815050E) to W.P.D. as well as The Burroughs Wellcome Fund and NIH/NHLBI HL091973 grants to K.M.C.

Disclosures

None.

References


67. Lin CI, Chen CN, Huang MT, Lee SJ, Lin CH, Chang CC, Lee H. LPA1 is inhibits transendothelial migration of medullary T cells to lymphatic sinuses.


72. Lee SJ, Chan TH, Chen TC, Liao BK, Hwang PP, Lee H. LPA1 is inhibits transendothelial migration of medullary T cells to lymphatic sinuses.


G Protein–Coupled Receptors as Potential Drug Targets for Lymphangiogenesis and Lymphatic Vascular Diseases
William P. Dunworth and Kathleen M. Caron

Arterioscler Thromb Vasc Biol. 2009;29:650-656; originally published online March 5, 2009; doi: 10.1161/ATVBAHA.109.185066
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/29/5/650

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/